Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01178 (oxytocin)
 15,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The concentration of MSH in serum after estrogen or progesterone injection into gonadectomized rats was measured by a biological assay. Undetectable serum MSH values were found in long-term ovariectomized (OVX) rats. After a single injection of 10 microgram estradiol benzoate (EB) serum MSH exhibited a circadiam rhythm with high levels in the afternoon, while values in the morning were negative. This effect occurred for 4 days following the injection. Progesterone injection into spayed rats also resulted in an increase of serum MSH concentration, but in contrast to the changes observed after EB treatment high values were found in the morning for 3 consecutive days. Afternoon MSH levels were low but measurable. The effect of these steroids on the activity of the hypothalamic enzymes which yielded MIF or MRF upon incubation with oxytocin (OXT) was also studied. Enzymatic activity of both systems was undetectable in OVX rats and was evident after EB treatment. Progesterone increased only the activity of the system which yields MRF. In castrated male rats estrogen elevated baseline MSH levels but a circadian rhythm was not observed, whereas progesterone had no effect. These observations demonstrate a sex difference on steroid-induced MSH release.
 ...
PMID:Effect of estrogen and progesterone on the release of MSH in gonadectomized rats. 2 14

The stimulating effect of different pituitary hormones on longitudinal bone growth was determined with tetracycline as intravital marker in hypophysectomized rats. Growth hormone was found to be the most effective growth stimulating pituitary hormone. At considerably higher doses, thyrotrophic hormone (TSH) and prolactin also showed growth stimulating pituitary hormone. At considerably higher doses, thyrotrophic hormone (TSH) and prolactin also showed growth stimulating activity. TSH exerts its effect via the production of thyroxine, whereas the growth stimulation by prolactin seems to be a direct effect of this hormone, similar to the effect of growth hormone. The LH, FSH, ACTH, MSH, vasopressin and oxytocin preparations did not stimulate longitudinal bone growth.
 ...
PMID:Stimulation of longitudinal bone growth by hypophyseal hormones in the hypophysectomized rat. 19 Aug 39

Mitochondrial preparations from stalk median eminence of female rats were shown to contain an enzymatic system which yielded MSH-RF upon incubation with oxytocin. These enzymes were found present in the hypothalamus of rats at proestrus and estrus and absent in the other stages of the cycle. The MSH contained in plasma was also determined during the estrous cycle in the rat. Serum MSH was released on the morning of proestrus, reached a maximum value at 10.00 a.m., and remained high until 4.00 p.m. Thereafter serum MSH decreased to undetectable levels in the other stages of the cycle. MSH was released into the serum about tectable levels in the other stages of the cycle. MSH was released into the serum about 6 h before the proestrous peak of the gonadotrophin. A correlation was demonstrated between the hypothalamic enzymes responsible for the formation of both MSH-F-IF and MSH-RF and the MSH released into the serum.
 ...
PMID:Serum MSH levels and the hypothalamic enzymes involved in the formation of MSH-RF during the estrous cycle in the rat. 81 Jul 34

The acyclic C-terminal tripeptide of oxytocin, H-Pro-Leu-Gly-NH-2, is not degraded upon incubation with human (male,female or pregnant female) plasma or serum for 1hr at 37 degrees. However, the sera of other species tested, including rat, chicken and carp, degrade this tripeptide 100%, 4% and 30%, respectively, in 1 hr, as determined by quantitative amino acid analysis of released products. Among the species studied there seems to exist a correlation between the anatomic development of the pars intermedia and the ability of the serum to hydrolyze H-Pro-Leu-Gly-NH-2, which has been proposed to be a MSH-release-inhibiting factor. The only identified degradation products are Pro, Leu and H-Gly-NH-2 with no detectable levels of H-Leu-Gly-NH2. The dipeptides H-Leu-Gly-NH-2 and H-Pro-Leu-OH are each cleaved at similiar rates in either human or rat serum, although the rate of hydrolysis of both peptides is lower in human than in rat. Thus, it does not appear that the dipeptide, H-EU-Gly-NH-2, can accumulate as one of the breakdown products of the tripeptide. The arylamidase present in rat serum has different characteristics from the enzyme in rat brain which can degrade H-Pro-Leu-Gly-NH-2.
 ...
PMID:Significant differences in the degradation of pro-leu-gly-nH2 by human serum and that of other species (38484). 116 15

Our laboratory has provided substantial evidence for the presence of PRL-releasing factor (PRF) in the posterior pituitary. The objectives of this study were 1) to determine the distribution of PRF activity between the neural and intermediate lobes, and 2) to assess the PRF activity of cultured posterior pituitary cells. Posterior pituitaries from adult male rats were dispersed with trypsin and cultured for 1-7 days. Cultured cells or intact posterior pituitaries were extracted with acid and lyophilized. PRF activity was determined by the ability of reconstituted extracts to increase PRL release from cultured anterior pituitary cells. Upon dissection of the posterior pituitary, PRF activity was primarily present in the intermediate lobe. There was minimal contamination between the two lobes, as indicated by the localization of 90% of the total oxytocin in the neural lobe and 95% of alpha MSH in the intermediate lobe. Extracts from intact posterior pituitaries and posterior pituitary cells cultured for 4 days stimulated PRL secretion in a similar dose-dependent manner. Cultured liver and cerebral cortex cells had very low PRF activity. Both oxytocin and dopamine, two neuronal markers, were reduced to less than 5% of their original values within 1 week of cell culture. There was also a significant reduction in the cell content of alpha MSH. On the other hand, PRF activity was relatively stable during culture. Incubation of posterior pituitary cells for 4 days with either cycloheximide or PRL caused a 55-60% reduction of the PRF activity of the cells. We conclude the following. 1) PRF is localized, almost exclusively, in the intermediate lobe of the pituitary. 2) PRF activity is present within nonneuronal cells, either melanotrophs or a small subpopulation of nonopioid-producing cells. 3) PRF is tissue specific, and its presence in cultured posterior pituitary cells depends at least in part on de novo synthesis. 4) The synthesis and/or release of PRF may be subjected to short loop negative feedback regulation by PRL.
 ...
PMID:Prolactin-releasing factor: cellular origin in the intermediate lobe of the pituitary. 211 57

Evidence is rapidly accumulating that a number of neuropeptides are involved in the central control of male sexual behavior. This is consistent with their neuroanatomical distribution, i.e., in CNS loci previously implicated in the control of this behavior such as the medial preoptic area, and with recent findings that the peptide content of some of these regions is regulated by testosterone or its metabolites. Most of the work has been done using rats, but relevant human studies have been included whenever such material has been available. At this point there are relatively few studies which directly demonstrate the involvement of peptides in this behavior. Inhibitory and facilitatory actions, however, have been demonstrated following injections of peptides, peptide antisera, or antagonists into the CNS of male rats. Significant new developments include demonstrations that injections of substance P and A-MSH directly into the medial preoptic area can facilitate this behavior, while ventricular injection of an oxytocin antagonist can produce a powerful inhibition. The emerging picture is that GnRH, oxytocin, A-MSH and substance P stimulate, while CRF, beta-endorphin, prolactin, and neuropeptide Y are inhibitory. The inhibitory peptides CRF, beta-endorphin and prolactin are related, as they are released in response to stress. This may be relevant to the low level of sexual motivation in some depressed men. Questions concerning sites of action and mechanisms of action which mediate the behavioral effects which have been demonstrated remain largely unanswered.
 ...
PMID:Neuropeptides and male sexual behavior. 267 29

Pharmacological influences on male rat sexual behavior are reviewed in an attempt to identify neurotransmitters and their respective receptor types that regulate various factors comprising the behavioral pattern. Evidence is presented that: (1) serotonergic influence is generally inhibitory to sexual behavior, although two receptor subtypes may lower ejaculation threshold; (2) dopaminergic agonists facilitate several aspects of copulatory behavior and ex copula genital responses; (3) noradrenergic activity appears to increase sexual arousal; (4) cholinergic agonists facilitate ejaculation, or in some cases, delay or prevent initiation of copulation; (5) GABA agonists inhibit sexual responses both in and ex copula; (6) opiate agonists appear to inhibit copulation and penile reflexes, although antagonists have mixed effects; (7) ACTH and MSH peptides promote copulatory behavior and genital responses; (8) oxytocin facilitates ex copula penile responses, but may contribute to postejaculatory refractoriness; and (9) long-term exposure to prolactin inhibits sexual behavior and penile responses. Although some progress has been made in identifying neurotransmitter-receptor effects on behavioral components, copulatory behavior is complex and no drug has been found to affect only a single component. Furthermore, drug specificity is only relative.
 ...
PMID:Pharmacological analysis of male rat sexual behavior. 283 May 64

Human placenta contains the POMC-derived peptides ACTH, alpha MSH, and beta-endorphin, and CRH. High concentrations of immunoreactive (IR) CRH have been recently demonstrated in maternal plasma during pregnancy. To determine if the human placenta secretes CRH and POMC-derived peptides, we developed an in vitro human placental fragment perifusion system. The perifused tissue released IR-CRH and POMC-derived peptides at a constant rate for at least 5 h. The mean IR-CRH concentration in the effluent (under basal conditions) was 158 +/- 26 (+/- SD) pg (34.5 +/- 5.8 fmol)/5-min fraction.g tissue. IR-alpha MSH, IR-beta-endorphin, and IR-ACTH were also released into the perifusion medium; the mean concentration of alpha MSH released was 24.6 +/- 8 pg (14.8 +/- 4.8 fmol)/fraction.g, that of ACTH was 2.9 +/- 1.9 pg (0.65 +/- 0.43 fmol)/fraction.g, and that of beta-endorphin was 12.9 +/- 6 pg (3.8 +/- 1.7 fmol)/fraction.g. We examined the effects of human CRH, oxytocin, vasopressin, and dexamethasone on placental POMC peptide secretion. Five-minute pulses of 10(-8) or 10(-6) mol/L human CRH or oxytocin produced an immediate and dose-dependent increase in all POMC peptides in the effluent. A 5-min pulse of 10(-8) or 10(-6) mol/L vasopressin had no effect. A continuous 4-h exposure to 10(-6) mol/L dexamethasone had no effect on either basal IR-CRH or POMC-derived peptide or their KCl-induced release. In conclusion, we found that 1) human placenta releases IR-CRH and POMC-derived peptides in vitro; this phenomenon seems to be independent of glucocorticoid control; 2) placental CRH may have a paracrine effect on placental POMC peptide release in addition to its possible action on maternal pituitary hormone release; and 3) oxytocin, but not vasopressin, stimulates placental POMC peptide release.
 ...
PMID:Corticotropin-releasing hormone and oxytocin stimulate the release of placental proopiomelanocortin peptides. 283 12

A tabular synopsis is presented for articles concerned with the effects of peptides on the central nervous system that appeared in the journal Peptides from 1980-1985. A table arranged alphabetically by peptide and one arranged by effects, both listing routes of injection, species, direction of change, and qualifying notes, provides easy cross-referencing of peptides and their effects. Over 80 peptides and over 135 effects are listed. The list of peptides includes, but is not limited to: ACTH, angiotensin, bombesin, bradykinin, calcitonin, casomorphin, CCK, ceruletide, CGRP, CRF, dermorphin, DSIP, dynorphin, endorphins, enkephalins, GRF, gastrin, LHRH, litorin, metkephamid, MIF-l, motilin, MSH, NPY, NT, oxytocin, ranatensin, sauvagine, substances P and K, somatostatin, TRH, VIP, vasopressin, and vasotocin. The list of effects includes, but is not limited to: aggression, alcohol, analgesia, attention, avoidance, behavior, cardiovascular regulation, catalepsy, conditioned behavior, convulsions, dopamine binding and metabolism, discrimination, drinking, EEG, exploration, feeding, fever, gastric secretion, GI motility, grooming, learning, locomotor behavior, mating, memory, neuronal activity, open field, operant behavior, rearing, respiration, satiety, scratching, seizure, sleep, stereotypy, temperature, thermoregulation and tolerance.
 ...
PMID:Central nervous system effects of peptides, 1980-1985: a cross-listing of peptides and their central actions from the first six years of the journal Peptides. 353 8

We determined the effect of oxytocin, alpha-melanocyte stimulating hormone (alpha-MSH) and arginine vasotocin on renal function of the macaque monkey. The only significant effect of the peptides was that alpha-MSH had an antidiuretic effect and vasotocin had both an antidiuretic and natriuretic effect.
 ...
PMID:Effects of oxytocin, vasotocin and alpha-MSH on renal function in the nonhuman primate. 397 37


1 2 3 4 5 Next >>